Provided by Tiger Trade Technology Pte. Ltd.

Takeda Pharmaceutical Co Ltd

18.24
+0.25501.42%
Volume:982.38K
Turnover:17.96M
Market Cap:58.03B
PE:-57.27
High:18.41
Open:18.23
Low:18.18
Close:17.98
52wk High:18.90
52wk Low:12.99
Shares:3.18B
Float Shares:3.09B
Volume Ratio:0.92
T/O Rate:0.03%
Dividend:0.62
Dividend Rate:3.42%
EPS(TTM):-0.3184
EPS(LYR):-0.3042
ROE:-2.26%
ROA:2.69%
PB:1.23
PE(LYR):-59.94

Loading ...

Denali Therapeutics regains full rights to DNL593

TIPRANKS
·
Apr 06

Analysts Are Bullish on Top Healthcare Stocks: Allogene Therapeutics (ALLO), Takeda Pharmaceutical Company (TAK)

TIPRANKS
·
Mar 31

Alumis' Drug 'Very Positive' for Treatment of Psoriasis, Systemic Lupus Erythematosus, Oppenheimer Says

MT Newswires Live
·
Mar 30

Takeda says Phase 3 zasocitinib pill clears plaque psoriasis skin in about 70% patients

Reuters
·
Mar 30

Takeda announces new data from Phase 3 studies of TAK-279

TIPRANKS
·
Mar 29

Takeda proposes Julie Kim for board election; Christophe Weber retires as CEO on June 24, 2026 shareholder vote

Reuters
·
Mar 26

Takeda Pharmaceutical to Book 1500 Billion Yen Restructuring Charge for AI-Driven Efficiency Overhaul

Stock News
·
Mar 25

Takeda Pharmaceutical Approves Restructuring Plan; Expects $1.26 Billion Annual Savings

MT Newswires Live
·
Mar 25

Market Chatter: Takeda, Eli Lilly to Face Class Action Over Actos Cancer Risk

MT Newswires Live
·
Mar 23

Takeda’s EXPLORHAE HAE Study in Egypt: Real‑World Data With Long‑Term Investor Upside

TIPRANKS
·
Mar 14

These 8 drugs could help fight dementia - and they're already on the market

Dow Jones
·
Mar 07

Takeda’s TAK-861 Narcolepsy Study Moves Forward, Extending the Long-Term Bet on Sleep Disorders

TIPRANKS
·
Mar 06

Takeda Advances Fazirsiran Phase 3 Liver Study, Keeping Rare-Disease Growth Story in Play

TIPRANKS
·
Mar 06

Sector Update: Health Care Stocks Advance Late Afternoon

MT Newswires Live
·
Mar 05

Market Chatter: Takeda Pharmaceutical to Cut 400 US Jobs, Invest in Blood Products

MT Newswires Live
·
Mar 05